Allerpha

Allerpha is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapies for allergic and autoimmune diseases. Headquartered in Suzhou, China, the company leverages its proprietary technology platforms to target key pathways in the type 2 inflammatory response. Its lead candidate, ALR-001, is a monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), currently being evaluated in Phase 2 clinical trials for allergic rhinitis and atopic dermatitis. The company's pipeline also includes programs targeting thymic stromal lymphopoietin (TSLP) and immunoglobulin E (IgE). Allerpha aims to address significant unmet medical needs in the rapidly growing allergy market through a robust portfolio of biologics. The company is supported by leading healthcare investors such as HighLight Capital and Sherpa Healthcare Partners.